The CARESS Project is a joint effort of 3 research institutions from Italy and France together with 4 SME's (small and medium sized entities) from Austria, France and Italy to develop an accurate, easy-to-use and cost efficient technology for determination of the DPD (dihydropyrimidine dehydrogenase) activity level.

The enzyme DPD is of crucial importance in the metabolism and deactivation of 5-FU (fluorouracil), a cytostatic drug most successfully and most commonly used in treatment of breast, colon and skin cancer.

In case of a genetically caused DPD deficiency 5-FU therapy will result in severe toxic reactions, which can be even fatal at the very first dose of 5-FU. Thus simple and reliable DPD activity screening is of essential importance for early detection of serious counter-indications for 5-FU therapy.


First Year Meeting in Paris on June 30, 2014

Review Meeting in Brussels on March 21, 2014

Mid Term Meeting in Vienna on December 4, 2013

Project posted at MyProject 2013 award

Kick-Off Meeting held in Rome on May 17, 2013

CARESS project started on May 1, 2013


read more ...

The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007-2013), managed by the REA - Research Executive Agency under the Grant Agreement n° 315398